Julia Felthaus
Overview
Explore the profile of Julia Felthaus including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
78
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Greil C, Engelhardt M, Felthaus J, Wasch R
Methods Mol Biol
. 2024 Nov;
2874:199-205.
PMID: 39614057
In order to sustain genomic stability by correct DNA replication and mitosis and thus avoid malignant transformation of cells, the cell cycle is a strictly regulated process. Aberrant cell cycle...
2.
Greil C, Felthaus J, Follo M, Ihorst G, Ewerth D, Schuler J, et al.
Am J Cancer Res
. 2021 Aug;
11(7):3698-3710.
PMID: 34354869
Targeting mitosis by taxanes is one of the most common chemotherapeutic approaches in various malignant solid tumors, but cancer cells may survive antimitotic treatment with attainable concentrations due to mitotic...
3.
Ewerth D, Kreutmair S, Schmidts A, Ihorst G, Follo M, Wider D, et al.
Cell Mol Life Sci
. 2018 Oct;
76(2):369-380.
PMID: 30357422
Hematopoietic stem and progenitor cells (HSPCs) represent the lifelong source of all blood cells and continuously regenerate the hematopoietic system through differentiation and self-renewal. The process of differentiation is initiated...
4.
Schnerch D, Schuler J, Follo M, Felthaus J, Wider D, Klingner K, et al.
Oncotarget
. 2017 Apr;
8(13):21153-21166.
PMID: 28416751
Elderly and frail patients, diagnosed with acute myeloid leukemia (AML) and ineligible to undergo intensive treatment, have a dismal prognosis. The small molecule inhibitor volasertib induces a mitotic block via...
5.
Schnerch D, Lausch E, Becker H, Felthaus J, Pfeifer D, Mundlos S, et al.
Leuk Lymphoma
. 2013 Oct;
55(8):1930-2.
PMID: 24138303
No abstract available.
6.
Schnerch D, Follo M, Felthaus J, Engelhardt M, Wasch R
PLoS One
. 2013 Sep;
8(9):e74379.
PMID: 24058555
Antimitotic agents are frequently used to treat solid tumors and hematologic malignancies. However, one major limitation of antimitotic approaches is mitotic slippage, which is driven by slow degradation of cyclin...
7.
Schnerch D, Schmidts A, Follo M, Udi J, Felthaus J, Pfeifer D, et al.
Haematologica
. 2013 Jul;
98(12):1886-95.
PMID: 23812934
Spindle poison-based therapy is of only limited benefit in acute myeloid leukemia while lymphoblastic leukemia/lymphoma responds well. In this study, we demonstrated that the spindle assembly checkpoint protein BubR1 was...
8.
Schnerch D, Follo M, Felthaus J, Engelhardt M, Wasch R
J Vis Exp
. 2012 Sep;
(67):e4239.
PMID: 23007658
Equal distribution of chromosomes between the two daughter cells during cell division is a prerequisite for guaranteeing genetic stability. Inaccuracies during chromosome separation are a hallmark of malignancy and associated...
9.
Schnerch D, Follo M, Krohs J, Felthaus J, Engelhardt M, Wasch R
Cell Cycle
. 2012 Jan;
11(2):310-21.
PMID: 22214763
Chromosome segregation is under strict control of the spindle assembly checkpoint (SAC). The SAC regulates anaphase-promoting complex/cyclosome (APC/C)-dependent proteolysis of securin and cyclin B. Unattached or misaligned chromosomes trigger SAC-mediated...
10.
Ngo B, Felthaus J, Hein M, Follo M, Wider D, Ihorst G, et al.
Leuk Lymphoma
. 2010 Jun;
51(9):1632-42.
PMID: 20578819
Cyclins D1, D2, and D3 (CCND1, 2, 3) are regulated by proteasomal degradation. Their overexpression in multiple myeloma (MM) has prognostic value. We performed this pilot study to analyze a...